Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based…
Manipal Hospital Sarjapur Road Empowers Fitness Enthusiasts with CPR Skills and First-Aid Workshop
BENGALURU, India, Oct. 14, 2025 /PRNewswire/ -- With the growing emphasis on…
Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu)…
Lamborghini SC63 finishes fourth in IMSA seasonending Petit Le Mans
Mortara-Kvyat-Grosjean fight for overall victory in the 10-hour Road Atlanta marathonSant’Agata Bolognese/Braselton,…
Idorsia successfully completes an upsized offering of shares funding the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION,…
Farizon SV shortlisted for International Van of the Year
Expert jurors from 26 countries select Farizon SV for IVOTY shortlist High…
DATROWAY Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to…
UST Earns Three CandE Awards for Candidate Experience Excellence in North America, EMEA, and APAC
Prestigious recognition includes number one overall rank for the EMEA region BENGALURU,…
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…